Dibawah ini ada tulisan mengenai Ok-432. Apakah fungsi Ok- 432=EtoxiSclerol ?
Salam Anton Goland ============ Sumber : http://www.surgjournal.com/article/PIIS0039606008004054/abstract? rss=yes Treatment of benign thyroid cysts by intracystic injection of OK-432 Jong-Lyel Roh, MD, PhDa, Chan Park II, MD, PhDb Accepted 6 June 2008. published online 01 September 2008. Background Benign thyroid cysts have been successfully treated with nonoperative sclerotherapy. Although OK-432 is a safe and effective sclerosing agent used to treat benign cystic lesions, little is known about its effectiveness in thyroid cysts. This study tested the efficacy of OK-432 sclerotherapy for thyroid cysts. Methods This was a prospective cohort study of 45 consecutive patients with benign thyroid cysts, as assessed by ultrasound (US)-guided biopsy. After evacuation, about 50% of the aspirated fluid volume was replaced with saline solution containing 0.1 to 0.2 mg OK-432. Recurrences were treated by repeat treatments, to a maximum of 3. Outcome was cyst volume on US 6 months after the last treatment. Results Median pretreatment cyst volume was 15 mL (range, 3.5110). Of the 45 patients, 33 (73%) were cured, defined as a residual cyst volume <1 mL; 20 were cured after 1 treatment, 8 after 2 treatments, and 5 after 3 treatments. Of the 12 patients (27%) not cured, 7 had >50% of the original cyst volume and 5 had <50% volume reduction; 3 of these patients underwent hemithyroidectomy. Multivariate analysis showed that the chance of success decreased with the number of previous aspirations and with increased cyst volume (P < .015 each). Transient mild local pain and low-grade fever were observed in 26 (58%) and 19 (42%) patients, respectively, but there were no significant treatment-related complications. Conclusions Intracystic injection of OK-432 may be a safe and effective treatment for benign thyroid cysts. a Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea b Department of Otolaryngology-Head and Neck Surgery, Chungnam National University College of Medicine, Daejeon, Republic of Korea Reprint requests: Jong-Lyel Roh, MD, PhD, Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, 388-1, Pungnap-dong, Songpa-gu, Seoul 138-736, Republic of Korea. Supported by a Korea Research Foundation Grant funded by the Korea Government (MOEHRD, Basic Research Promotion Fund) (KRF-2007-331- E00146), and by the Ministry of Health & Welfare, the National R&D Program for Cancer Control (Grant No. 0620160), Seoul, Republic of Korea. PII: S0039-6060(08)00405-4 doi:10.1016/j.surg.2008.06.014 © 2008 Mosby, Inc. All rights reserved.
